{"numRecords":"120","DataElementQueryResults":[{"publicId":"3775996","version":"1","preferredName":"Race Category Multiracial Race Category","preferredDefinition":"The text for reporting information about race based on the Office of Management and Budget (OMB) categories.","longName":"MULTI_RACE_CAT_TXT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE833B93-B78B-4010-E040-BB89AD437C42","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-10-07","changeNote":"OHSU  7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776029","version":"1","preferredName":"Participant Trial Screening Identifier","preferredDefinition":"Unique screening identifier for a study participant","longName":"PT_TRIAL_SCRN_ID","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE833B93-BA00-4010-E040-BB89AD437C42","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SOKKERL","dateModified":"2017-08-23","changeNote":"05/25/2016 wz added NWU CS/CSI. OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776094","version":"1","preferredName":"Chemosensitivity Assay Agent Name","preferredDefinition":"The agent (active power or cause) name used in a laboratory test to see how well a particular chemotherapy drug kills cancer cells which may result in choosing the best drug or drugs for the treatment of the specific cancer being treated.","longName":"CHEMO_ASSAY_AGENT_NAME","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84A65B-7B1E-2E67-E040-BB89AD432F22","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776131","version":"1","preferredName":"Subject Continue Clinical Study Screening Indicator","preferredDefinition":"The yes/no response regarding whether an individual will continue with processes to consider them as potential subjects for enrollment in a research conducted on human subjects.","longName":"3776113v1.0:3506068v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE85304D-4B44-7560-E040-BB89AD43263E","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SPRINGERL","dateModified":"2019-04-09","changeNote":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776154","version":"1","preferredName":"Subject Continue Clinical Study Trial Screening Discontinued Trial Screening Reason","preferredDefinition":"The reason the subject discontinued the trial screening.","longName":"3776113v1.0:3776152v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE858BA0-4079-8022-E040-BB89AD435A9A","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"CLOHNES","dateModified":"2023-05-09","changeNote":"OHSU 7195 ghd 06.06.13","administrativeNotes":"5/9/23 added human readable definition per cleanup activities for OHSU Knight cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776172","version":"1","preferredName":"Clinical Trial Eligibility Criteria Category","preferredDefinition":"A class of criteria (inclusion or exclusion) that are used to evaluate candidates for enrollment into a clinical trial.","longName":"2012996v3.0:3776171v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE85E30F-B9B6-65BD-E040-BB89AD43667A","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-10-08","changeNote":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776193","version":"1","preferredName":"Study Agent First Administration Indicator","preferredDefinition":"The yes/no response regarding whether this is the first administration of study agent medication given to the patient while enrolled on this study.","longName":"3776192v1.0:3506068v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE8611B7-E7F0-D539-E040-BB89AD435509","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"HARTLEYG","dateModified":"2013-07-02","changeNote":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776198","version":"1","preferredName":"Concomitant Agent Pretreatment Period Administered Indicator","preferredDefinition":"The yes/no response regarding whether a concomitant agent was administered prior to the time of administration of the treatment of interest.","longName":"3776197v1.0:3506068v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE8611B7-E864-D539-E040-BB89AD435509","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"HARTLEYG","dateModified":"2013-07-02","changeNote":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3776898","version":"1","preferredName":"Patient Pregnancy Test Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether a pregnancy test has been performed.","longName":"PREG_TEST_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE9DA350-CF04-B4C9-E040-BB89AD430247","latestVersionIndicator":"Yes","beginDate":"2013-06-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-08","modifiedBy":"KUMMEROA","dateModified":"2024-02-16","changeNote":"OHSU 7195 ghd 06.07.13","administrativeNotes":"2024.2.16 AQT added per ticket request CADSR0003416. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3778558","version":"1","preferredName":"Pathology Report Findings Text","preferredDefinition":"Descriptive text used to enumerate pathologic observations.","longName":"PATH_REP_FIND_TXT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED3B883-92A7-9E18-E040-BB89AD433247","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"TSESU","dateModified":"2023-11-27","changeNote":"OHSU. 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3778572","version":"1","preferredName":"FISH Assessment Test Cytogenetic Analysis Text","preferredDefinition":"Text used to describe the results of analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities (cytogenetic testing) related to fluorescence in situ hybridization (FISH) test assessment.","longName":"2192068v1.0:3778571v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED3B883-92DD-9E18-E040-BB89AD433247","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3778573","version":"1","preferredName":"Cytogenetic Analysis Text","preferredDefinition":"Text describing a finding upon examination and interpretation of cytological and molecular behavior of genes and chromosomes during cell division.","longName":"CYTO_ANALY_TEXT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED3B883-9308-9E18-E040-BB89AD433247","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SOKKERL","dateModified":"2020-04-27","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3778593","version":"1","preferredName":"Disease Status Leukemia Chemosensitivity Type","preferredDefinition":"the status of a disease._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities._A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","longName":"2177998v1.0:3778591v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED4C78D-795C-AD52-E040-BB89AD4360A2","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781080","version":"1","preferredName":"Acute Myeloid Leukemia Disease Response Status","preferredDefinition":"AML response based on Cheson criteria adapted by Stephen Spurgeon, M.D","longName":"2190138v1.0:3781060v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DD0B-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781081","version":"1","preferredName":"Acute Lymphoblastic Leukemia Disease Response Status","preferredDefinition":"ALL response based on Cheson criteria adapted by Stephen Spurgeon, M.D.","longName":"2190138v1.0:3781075v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED8A5EC-4021-159A-E040-BB89AD4319B1","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781084","version":"1","preferredName":"Leukemia Disease Response Status","preferredDefinition":"Best response for study participant as applicable to either Acute Myelogenous Leukemia or Acute Lymphoblastic Leukemia, based on Cheson criteria adapted by Stephen Spurgeon, M.D","longName":"2190138v1.0:3781083v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED8A5EC-410C-159A-E040-BB89AD4319B1","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"HARTLEYG","dateModified":"2013-07-02","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781144","version":"1","preferredName":"Modified Dose Counts","preferredDefinition":"Modified; changed in form or character._A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._counts that indicate the quantity of a specified item.","longName":"3781143v1.0:2178233v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED92045-0C27-B64B-E040-BB89AD432331","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"HARTLEYG","dateModified":"2013-07-02","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781147","version":"1","preferredName":"Interventions Modified Interrupted Or Not Completed Reason","preferredDefinition":"Text response that explains modifications to acts that can have preventive and/or therapeutic impact or reason acts not completed.","longName":"3781146v1.0:3028818v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED92045-0C66-B64B-E040-BB89AD432331","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"OHSU. 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781148","version":"1","preferredName":"Interventions Modified Descriptive Text","preferredDefinition":"Text that provides a description of modification of an activity or measure that produces an effect or that is intended to alter the course of a disease in patient or population.  This is a general term encompassing medical, social, behavioral, environmental and other acts that can have preventive and/or therapeutic impact.","longName":"3781146v1.0:2181231v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED92045-0C90-B64B-E040-BB89AD432331","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"TITARENKOI","dateModified":"2020-05-27","changeNote":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3781555","version":"1","preferredName":"Dose Modification Completion Status","preferredDefinition":"Information describing the condition or state or the type of change related to dose modification (change from original state).","longName":"2184763v1.0:2871582v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DEE8B630-9AC3-DD16-E040-BB89AD437A5F","latestVersionIndicator":"Yes","beginDate":"2013-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-11","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"OHSU 7195 ghd 06.11.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4503851","version":"1","preferredName":"Coordinating Center Investigator Signature Indicator","preferredDefinition":"The yes/no response regarding whether the investigator at the facility responsible for receiving editing, processing, analyzing and storing data generated in a study has signed his/her name in confirmation.","longName":"CO_CTR_INV_SIG_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0477E8A3-A58C-0F54-E050-BB89AD43487A","latestVersionIndicator":"Yes","beginDate":"2014-10-02","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-02","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.078.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4503878","version":"1","preferredName":"Person Height Weight Assessment Date","preferredDefinition":"The response regarding the date that a person's height and weight were measure for participation in a clinical trial.","longName":"PER_HT_WT_AS_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"047A1203-C54F-9B6A-E050-BB89AD4379B0","latestVersionIndicator":"Yes","beginDate":"2014-10-02","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-02","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.078.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4503931","version":"1","preferredName":"Spleen Ultrasound Size Assessment Indicator","preferredDefinition":"The yes/no response regarding whether the physical magnitude/size of a the patient's spleen was determined utilizing ultrasound testing.","longName":"SPL_ULTSND_SZ_AS_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04825E80-EC36-519D-E050-BB89AD431DF8","latestVersionIndicator":"Yes","beginDate":"2014-10-03","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-03","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.078.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4503991","version":"1","preferredName":"Immunophenotype Flow Cytometry Performed Findings Text","preferredDefinition":"Immunophenotype is the characterization of a set of cells according to the antigens expressed._A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid._Executed and carried through to completion._Results of a test, procedure, or examination.","longName":"3987737v1.0:2016967v4.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04845D45-55F5-F23D-E050-BB89AD4301FE","latestVersionIndicator":"Yes","beginDate":"2014-10-03","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-03","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4508233","version":"1","preferredName":"Spleen Width Size Measurement","preferredDefinition":"The numerical value that represents the measurement of the spleen from side to side.","longName":"SPL_WID_SZ_MEA","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04A237E8-4088-5861-E050-BB89AD432B9D","latestVersionIndicator":"Yes","beginDate":"2014-10-04","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-04","modifiedBy":"BRADLAUR","dateModified":"2014-10-12","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4508253","version":"1","preferredName":"Spleen Thickness Size Measurement","preferredDefinition":"The numerical value that represents the distance between two surfaces of the spleen that represents the smallest dimension as opposed to the width or length.","longName":"SPL_THI_SZ_MEA","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04A237E8-40C3-5861-E050-BB89AD432B9D","latestVersionIndicator":"Yes","beginDate":"2014-10-04","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-04","modifiedBy":"BRADLAUR","dateModified":"2014-10-12","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4508256","version":"1","preferredName":"Spleen Maximum Length Size Measurement","preferredDefinition":"The numerical value that represents the linear extent from one end of the spleen to the other.","longName":"SPL_MAX_LEN_SZ_MEA","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04A237E8-40FE-5861-E050-BB89AD432B9D","latestVersionIndicator":"Yes","beginDate":"2014-10-04","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-04","modifiedBy":"CHANGP","dateModified":"2017-04-17","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4508273","version":"1","preferredName":"Spleen Palpation Indicator","preferredDefinition":"The yes/no response regarding whether the spleen was felt using the physician's hands during an examination.","longName":"SPL_PAL_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04A2CAB9-8A11-5339-E050-BB89AD430A28","latestVersionIndicator":"Yes","beginDate":"2014-10-04","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-04","modifiedBy":"BRADLAUR","dateModified":"2014-10-12","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4508313","version":"1","preferredName":"Adverse Event Duration Type","preferredDefinition":"The response describing the length of time an adverse event continued.","longName":"AE_DUR_TYP","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04A37831-AE76-C1A2-E050-BB89AD437171","latestVersionIndicator":"Yes","beginDate":"2014-10-04","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2014-10-04","modifiedBy":"FORMBUILDER","dateModified":"2015-09-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4530250","version":"1","preferredName":"Agent Dose Level Value","preferredDefinition":"The response regarding the quantity of an agent administered at one time to a patient treated on a clinical trial.","longName":"AGT_DOS_LEV_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0506DB80-9B82-DCAE-E050-BB89AD43083B","latestVersionIndicator":"Yes","beginDate":"2014-10-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-09","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.09.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4530254","version":"1","preferredName":"Transfusion Last Year Information Collected Indicator","preferredDefinition":"The yes/no response regarding whether information pertaining to any transfusions has been collected for the past year.","longName":"4530253v1.0:3506068v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"050729B2-9408-8422-E050-BB89AD431824","latestVersionIndicator":"Yes","beginDate":"2014-10-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-09","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.09.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4530256","version":"1","preferredName":"Transfusion Last Year Information Collected Date","preferredDefinition":"The date response regarding when information collected for the past year pertaining to any transfusions was entered into the database.","longName":"TRA_LA_YR_INF_COL_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"050729B2-9434-8422-E050-BB89AD431824","latestVersionIndicator":"Yes","beginDate":"2014-10-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-09","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.09.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4530271","version":"1","preferredName":"Transfusion Received Blood Transfusion Reason","preferredDefinition":"The text explanation regarding the reasons for administering a transfusion of blood components or whole blood during treatment for cancer.","longName":"BL_TRA_RCV_RSN","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"050AE253-2195-F2F2-E050-BB89AD437A77","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FOURNIERLA","dateModified":"2017-01-16","changeNote":"Added new PV_ 01/16/2017_LF  10262_OHSU_10.09.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531714","version":"1","preferredName":"Patient Pre-existing Condition Current Therapy Administered Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether a patient is currently receiving therapy of any kind for a pre-existing condition at the time of an evaluation.","longName":"PT_PRE_CON_TX_ADM_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05144A63-654D-5CC6-E050-BB89AD436095","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531737","version":"1","preferredName":"Spleen Volume Organ Assessment Measurement","preferredDefinition":"The numerical value that represents the three dimensional space occupied by the spleen.","longName":"SPL_VOL_ORG_AS_MEA","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05144A63-66DD-5CC6-E050-BB89AD436095","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"BRADLAUR","dateModified":"2014-10-12","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531787","version":"1","preferredName":"Spleen Palpable Size Measurement Centimeter Value","preferredDefinition":"The numerical value that represents the measurement in centimeters of the spleen by being touched or felt.","longName":"SPL_PAL_SZ_MEA_CM_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05158AD9-1736-FC56-E050-BB89AD435CD1","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531793","version":"1","preferredName":"Study Agent Not Dispensed Reason Text","preferredDefinition":"The text response regarding the reason a study agent was not dispensed to a patient participating in a clinical trial.","longName":"ST_AGT_NT_DIS_RSN_TXT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05158AD9-17A0-FC56-E050-BB89AD435CD1","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4531814","version":"1","preferredName":"Study Agent Returned Negation Reason Text","preferredDefinition":"The text response explaining the reason that study drug was not returned.","longName":"S_AGT_RET_NEG_RSN_TXT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05158AD9-1811-FC56-E050-BB89AD435CD1","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"10262_OHSU_10.10.14_gdh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4533283","version":"1","preferredName":"Myelodysplastic Syndrome International Prognostic Index Indicator","preferredDefinition":"The yes/no response regarding whether the International Prognostic Index has been administered.","longName":"MYE_SYN_IPSS_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05174F7B-1B65-8825-E050-BB89AD435C77","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4533477","version":"1","preferredName":"Abnormal Immunophenotype Flow Cytometry Observed Indicator","preferredDefinition":"The yes/no indicator response regarding whether an abnormal immunophenotype was observed as a result of Flow Cytometry.","longName":"ABN_IMM_FLOW_OBS_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"051B772E-80AC-C799-E050-BB89AD4334FD","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4533481","version":"1","preferredName":"Skin Biopsy Collected Indicator","preferredDefinition":"The yes/no response regarding whether a portion of skin tissue was collected and removed for examination.","longName":"SKI_BIO_COL_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"051B772E-80EC-C799-E050-BB89AD4334FD","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4533497","version":"1","preferredName":"International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes Criterion Type","preferredDefinition":"The response regarding the type of criterion used in determining the International Prognostic Scoring System score for patients diagnosed with myelodysplasia syndromes.","longName":"IPSS_CRIT_TYP","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"051C0505-4F1B-A989-E050-BB89AD433321","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"BRADLAUR","dateModified":"2014-10-11","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4533511","version":"1","preferredName":"Skin Biopsy Other Timepoint Collected Specify Text","preferredDefinition":"Removal of a portion of skin tissue, for microscopic examination._Different than the one(s) previously specified or mentioned._A specific point in the time continuum, including those established relative to an event._Collected; brought together in one place._Be specific about something; define clearly._Text; the words of something written.","longName":"SK_BIO_OTH_TP_COL_TEX","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"051CA85B-9D4A-07BA-E050-BB89AD432C0A","latestVersionIndicator":"Yes","beginDate":"2014-10-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"10262_OHSU_10.10.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4534704","version":"1","preferredName":"Fluorescence in situ Hybridization Cytogenetics Abnormal Present Indicator","preferredDefinition":"The yes/no response regarding whether the in situ hybridization displays a pattern of staining that would indicate abnormal sequences.","longName":"FLOW_CYT_ABN_PRE_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05522064-8155-8009-E050-BB89AD436CF6","latestVersionIndicator":"Yes","beginDate":"2014-10-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-13","changeNote":"10262_OHSU_10.13.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4536068","version":"1","preferredName":"Persistent Leukocytosis Present Indicator","preferredDefinition":"The yes/no response that indicates an increased number of white blood cells in the peripheral blood.","longName":"PERS_LEUKOCTS_PRES_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0568B6B6-FAD1-7667-E050-BB89AD430AC6","latestVersionIndicator":"Yes","beginDate":"2014-10-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-14","modifiedBy":"BRADLAUR","dateModified":"2015-08-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4536069","version":"1","preferredName":"BCR/ABL1 Fusion Gene Present Indicator","preferredDefinition":"The yes/no response indicating a fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of the ABL1 gene.","longName":"BCR_ABL1_FUSN_GENE_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0568B6B6-FAF0-7667-E050-BB89AD430AC6","latestVersionIndicator":"Yes","beginDate":"2014-10-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-14","modifiedBy":"MAESKEB","dateModified":"2014-10-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4536070","version":"1","preferredName":"PDGFRA Gene Rearrangement Present Indicator","preferredDefinition":"The yes/no response indicating the rearrangement of the PDGFRA gene, resulting in the formation of a fusion transcript and aberrant tyrosine kinase activity.","longName":"PDGFRA_GENE_REARRANG_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0568B6B6-FB0F-7667-E050-BB89AD430AC6","latestVersionIndicator":"Yes","beginDate":"2014-10-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-14","modifiedBy":"MAESKEB","dateModified":"2014-10-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4536071","version":"1","preferredName":"PDGFRB Gene Rearrangement Present Indicator","preferredDefinition":"The yes/no response that indicates the rearrangement of the PDGFRB gene, resulting in the formation of a fusion transcript and aberrant tyrosine kinase activity.","longName":"PDGFRB_GENE_REARRANG_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0568B6B6-FB2E-7667-E050-BB89AD430AC6","latestVersionIndicator":"Yes","beginDate":"2014-10-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-14","modifiedBy":"SORTILLD","dateModified":"2019-09-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4536072","version":"1","preferredName":"FGFR1 Gene Rearrangement Present Indicator","preferredDefinition":"The yes/no response that indicates the rearrangement of the FGFR1 gene resulting in translocations with an 8p11 breakpoint. It has been described in hematologic malignancies presenting as myeloproliferative neoplasms or acute leukemias.","longName":"FGFR1_GENE_REARRANG_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0568B6B6-FB4D-7667-E050-BB89AD430AC6","latestVersionIndicator":"Yes","beginDate":"2014-10-14","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-14","modifiedBy":"MAESKEB","dateModified":"2014-10-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4539333","version":"1","preferredName":"Bone Marrow Involvement Laboratory Status","preferredDefinition":"The responses related to bone marrow involved by disease.","longName":"BN_MARW_INVOLV_LAB_STATS","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"059FDCB7-B839-5638-E050-BB89AD43589D","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-17","modifiedBy":"MAESKEB","dateModified":"2014-10-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4541515","version":"1","preferredName":"Laboratory Procedure Granulocytic Hyperplasia of Bone Marrow Finding Character Value","preferredDefinition":"Percent of marrow containing granulocytic cells.","longName":"LAB_PROC_GH_BM_FNG_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DD47CF-8F9E-32D3-E050-BB89AD4317B9","latestVersionIndicator":"Yes","beginDate":"2014-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-20","modifiedBy":"MAESKEB","dateModified":"2014-10-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4541520","version":"1","preferredName":"Laboratory Procedure Granulocytic Dysplasia of Bone Marrow Finding Percentage Value","preferredDefinition":"Percent of granulocytic cells displaying dysplasia, as defined by the WHO.","longName":"LAB_PROC_GD_BM_FNG_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DD47CF-8FE9-32D3-E050-BB89AD4317B9","latestVersionIndicator":"Yes","beginDate":"2014-10-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-20","modifiedBy":"MAESKEB","dateModified":"2014-10-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4549871","version":"1","preferredName":"Bone Marrow Biopsy Myeloid Erythroid Ratio Character Value","preferredDefinition":"Ratio of myeloid to erythroid precursors in the bone marrow.  Usually 3-4:1 in a normal marrow.","longName":"BM_BX_MYL_ERY_RT_CHAR_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05EF5B40-9BFC-47C4-E050-BB89AD43166F","latestVersionIndicator":"Yes","beginDate":"2014-10-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-21","modifiedBy":"REEVESD","dateModified":"2016-10-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566152","version":"1","preferredName":"Report Institutional Review Board Submission Date","preferredDefinition":"The response regarding the date that a textual account/report is submitted for consideration by the Intitutional Review Board.","longName":"RPT_IRB_SUB_DAT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06958B2A-8278-A6E6-E050-BB89AD43569A","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"KNABLEJ","dateModified":"2018-11-07","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566153","version":"1","preferredName":"Protocol Deviation Action Indicator","preferredDefinition":"The yes/no/unknown response regarding whether action resulted from the submission of information regarding a deviation to the institutional review board.","longName":"PRO_DEV_ACT_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06958B2A-8298-A6E6-E050-BB89AD43569A","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"FORMBUILDER","dateModified":"2015-09-16","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566179","version":"1","preferredName":"Neutrophilia Other Etiology Indicator","preferredDefinition":"The yes/no response regarding whether there is another cause of abnormally high levels of neutrophils in the blood aside from those already listed.","longName":"NEU_OTH_ETI_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06958B2A-82DB-A6E6-E050-BB89AD43569A","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566692","version":"1","preferredName":"CSF3R Gene Allele Burden Percentage Value","preferredDefinition":"The numeric response regarding the measurement of the percentage ratio between mutant and wild type CSF3R genes in hematopoietic cells.","longName":"CSF3R_ALL_BUR_PER_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"069908FB-2CA8-43A9-E050-BB89AD431C69","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566693","version":"1","preferredName":"SETBP1 Gene Allele Burden Percentage Value","preferredDefinition":"The numeric response regarding the measurement of the percentage ratio between mutant and wild type SETBP1 genes in hematopoietic cells.","longName":"SETBP1_AL_BUR_PER_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"069908FB-2CC8-43A9-E050-BB89AD431C69","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566694","version":"1","preferredName":"Other Mutation Abnormality Allele Burden Percentage Value","preferredDefinition":"The numeric response regarding the measurement of the percentage ratio between mutant and wild type genes, other than those previously specified, in hematopoietic cells.","longName":"OT_MU_AL_BUR_PER_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"069908FB-2CE8-43A9-E050-BB89AD431C69","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"MORENOC","dateModified":"2020-01-23","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566714","version":"1","preferredName":"Disease or Disorder Clinical Suspicion Diagnosis Date","preferredDefinition":"The response regarding the date of the of initial preliminary tests/procedures completed that led the clinical team to suspect disease/disorder before a definitive diagnosis was made.","longName":"DIS_CLIN_SUS_DX_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"069908FB-2D2E-43A9-E050-BB89AD431C69","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-29","modifiedBy":"FORMBUILDER","dateModified":"2018-07-11","changeNote":"10262_OHSU_10.29.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566912","version":"1","preferredName":"Disease Response Spleen Ultrasound Assessment Status","preferredDefinition":"The response regarding the state of clinical changes to spleen size assessed by ultrasound as a result of treatment.","longName":"DS_RES_SPL_ULT_AS_ST","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06A77FFB-4AE8-40ED-E050-BB89AD4369C8","latestVersionIndicator":"Yes","beginDate":"2014-10-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-30","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566913","version":"1","preferredName":"Disease Response Spleen Palpation Assessment Status","preferredDefinition":"The response regarding the state of clinical changes to spleen size assessed by palpation during a physical exam as a result of treatment.","longName":"DS_RES_SPL_PAL_AS_ST","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06A77FFB-4B08-40ED-E050-BB89AD4369C8","latestVersionIndicator":"Yes","beginDate":"2014-10-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-30","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566914","version":"1","preferredName":"Disease Response Granulocyte Dysplasia Assessment Status","preferredDefinition":"The response regarding the state of pathologic and/or clinical changes to granulocyte neoplastic transformation as a result of treatment.","longName":"DS_RES_GRA_DYS_AS_ST","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06A77FFB-4B28-40ED-E050-BB89AD4369C8","latestVersionIndicator":"Yes","beginDate":"2014-10-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-30","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566915","version":"1","preferredName":"Disease Response Granulocyte Hyperplasia Assessment Status","preferredDefinition":"The response regarding the state of pathologic and/or clinical changes to the number of granulocyte in an organ resulting in enlargement as a result of treatment.","longName":"DS_RES_GRA_HYP_AS_ST","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06A7BF5D-9E02-1FCC-E050-BB89AD430E8D","latestVersionIndicator":"Yes","beginDate":"2014-10-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-30","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566934","version":"1","preferredName":"Laboratory Procedure Coagulation Process Specimen Collected Date","preferredDefinition":"The response regarding the date that a blood sample was collected for testing coagulation factors interacting to form a fibrin clot.","longName":"LAB_COAG_SPE_COL_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06A7BF5D-9E7A-1FCC-E050-BB89AD430E8D","latestVersionIndicator":"Yes","beginDate":"2014-10-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-30","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4566935","version":"1","preferredName":"Laboratory Procedure Coagulation Process Specimen Collected Indicator","preferredDefinition":"The yes/no response regarding whether a blood sample was collected for testing blood coagulation.","longName":"LAB_COAG_SPE_COL_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06A7BF5D-9E9A-1FCC-E050-BB89AD430E8D","latestVersionIndicator":"Yes","beginDate":"2014-10-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-10-30","modifiedBy":"HARTLEYG","dateModified":"2014-10-30","changeNote":"10262_OHSU_10.30.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4570832","version":"1","preferredName":"Laboratory Procedure Activated Partial Thromboplastin Time Result Value","preferredDefinition":"The response regarding the value for level of activated partial thromboplastin time in seconds measured to the tenth of a second, a measurement of the intrinsic pathway of coagulation.","longName":"LAB_APTT_RSLT_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FC4929-BF85-04A8-E050-BB89AD43562F","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"BRADLAUR","dateModified":"2014-11-04","changeNote":"10262_OHSU_11.04.14_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4976339","version":"1","preferredName":"Performance Status Assessment Indicator","preferredDefinition":"The yes/no indicator related to whether or not performance status assessment (information related to the final result of a determination of the value, significance, or extent of how well a patient is able to perform ordinary tasks and carry out daily activities) was obtained.","longName":"2486204v1.0:3506068v1.0","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DC5FA96-67B0-8A34-E050-BB89AD4344BC","latestVersionIndicator":"Yes","beginDate":"2015-08-20","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-08-20","modifiedBy":"LEEW","dateModified":"2018-10-17","changeNote":"Curated because we needed a generic perf. status collected question not specific to a specific type (e.g. ECOG or Karnofsky).  Curator:  Lara Fournier","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5002391","version":"1","preferredName":"Laboratory Procedure Urine Free Kappa Light Chain Measurement","preferredDefinition":"Information related to the result of the medical procedure that involves testing a sample of urine, the fluid that is excreted by the kidneys for Kappa immunoglobulin light chain, one of the two light chain proteins that are part of the protein complex found in abundance in patients who have multiple myeloma and is expressed in malignant plasma cells and excreted into the blood and urine._Number that is expressed as maximum of eight characters in length, with three decimal places.","longName":"LAB_URN_KAPPA_LT_CHN_3DP_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F093FFA-601C-EE84-E050-BB89AD433950","latestVersionIndicator":"Yes","beginDate":"2015-09-05","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-05","modifiedBy":"BRADLAUR","dateModified":"2015-09-28","changeNote":"CDE curated by L Bradley, OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5002392","version":"1","preferredName":"Laboratory Procedure Urine Free Lambda Light Chain Measurement","preferredDefinition":"Information related to the result of the medical procedure that involves testing a sample of urine, the fluid that is excreted by the kidneys for Lambda immunoglobulin light chain, one of the two light chain proteins that are part of the protein complex found in abundance in patients who have multiple myeloma and is expressed in malignant plasma cells and excreted into the blood and urine.","longName":"LAB_URN_LAMBDA_LT_CHN_3DP_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F093FFA-603B-EE84-E050-BB89AD433950","latestVersionIndicator":"Yes","beginDate":"2015-09-05","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-05","modifiedBy":"BRADLAUR","dateModified":"2015-09-28","changeNote":"New CDE curated by L. Bradley, OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5002911","version":"1","preferredName":"Personal Medical History Disease or Disorder Prior Transplant Conditioning Continue","preferredDefinition":"The Yes/No/Unknown indicator related to a person having any abnormal condition of the body or mind as an element of a personal medical history prior to conditioning therapy in preparation for a bone marrow or hematopoietic stem cell transplant.","longName":"MED_HX_ONGOING_PRIOR_CONDTNING","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F469BF9-E2D3-4BA4-E050-BB89AD434672","latestVersionIndicator":"Yes","beginDate":"2015-09-08","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-08","modifiedBy":"BRADLAUR","dateModified":"2015-09-28","changeNote":"New CDE curated by L. Bradley - OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5002912","version":"1","preferredName":"Personal Medical History Disease or Disorder Agent Administration (Dispense) Continue","preferredDefinition":"The Yes/No/Unknown indicator related to a person having any abnormal condition of the body or mind as an element of a personal medical history that continues after the person receives an agent (e.g. a drug).","longName":"MED_HX_ONGOING_AGNT_DSPENSE_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F469BF9-E2F3-4BA4-E050-BB89AD434672","latestVersionIndicator":"Yes","beginDate":"2015-09-08","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-08","modifiedBy":"BRADLAUR","dateModified":"2015-09-28","changeNote":"New CDE curated by L. Bradley - OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5005071","version":"1","preferredName":"Patient Bone Marrow Blast Cell Decrease Outcome Indicator","preferredDefinition":"A yes/no question that indicates whether the patient has experienced a protocol-specified decrease in bone marrow blast cells from baseline [manually curated].","longName":"PT_BM_BLST_DEC_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F66F27E-6183-A2FB-E050-BB89AD434599","latestVersionIndicator":"Yes","beginDate":"2015-09-10","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-09-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"curated for protocol 7195","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5010417","version":"1","preferredName":"Laboratory Procedure Bone Marrow Cellularity Outcome Cell Count Change from Baseline Percent","preferredDefinition":"information related to medical procedure that involves testing a sample bone marrow, the soft tissue filling the cavities of bones, for he degree, quality, or condition of cells that are present._Percentage of change in a cell count measurement or assessment from the baseline evaluation.","longName":"BM_CELLU_PCT_CHG","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F7D5349-B2E5-FBE0-E050-BB89AD4321FD","latestVersionIndicator":"Yes","beginDate":"2015-09-11","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-09-11","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"Needed new CDE for 7195","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5010431","version":"1","preferredName":"Peripheral Blast Cell Change from Baseline Percent","preferredDefinition":"Percentage of change in peripheral blast cell measurement or assessment from the baseline evaluation [manually curated].","longName":"PER_BLST_CELL_PCT_CHG","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F811747-0DBD-EA24-E050-BB89AD437BED","latestVersionIndicator":"Yes","beginDate":"2015-09-11","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-09-11","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"Needed new CDE for 7195 protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5010432","version":"1","preferredName":"Bone Marrow Blast Cell Change from Baseline Percent","preferredDefinition":"Percentage of change in bone marrow blast cell measurement or assessment from the baseline evaluation [manually curated].","longName":"BM_BLST_CELL_PCT_CHG","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F812E6E-62EE-59B5-E050-BB89AD4323C5","latestVersionIndicator":"Yes","beginDate":"2015-09-11","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-09-11","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeNote":"needed new CDE for 7195 protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5012354","version":"1","preferredName":"Specimen Laboratory Processing Date","preferredDefinition":"The date a specimen sample was processed by a laboratory or banking institution [manually curated].","longName":"SPEC_PROC_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F82042B-BC4B-9B71-E050-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2015-09-11","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-09-11","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeNote":"Needed new CDE for 7195 protocol","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5015383","version":"1","preferredName":"Minimal Residual Disease Assessment Status","preferredDefinition":"The final result of a determination of the value, significance, or extent of the remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.","longName":"MRD_ASSESS_STATUS","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1FD261D8-9B90-33EA-E050-BB89AD437DED","latestVersionIndicator":"Yes","beginDate":"2015-09-15","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-15","modifiedBy":"MORENOC","dateModified":"2018-07-09","changeNote":"New CDE curated by L. Bradley - OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5021811","version":"1","preferredName":"Personal Medical History Disease or Disorder Diagnosis","preferredDefinition":"The Yes/No/Unknown/Not Applicable indicator for information related to a person having any abnormal condition of the body or mind as an element of a personal medical history that was found as the result of the investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms","longName":"MED_HX_DX_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20479670-5654-EECF-E050-BB89AD437151","latestVersionIndicator":"Yes","beginDate":"2015-09-21","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-21","modifiedBy":"BRADLAUR","dateModified":"2015-09-28","changeNote":"New CDE curated by L. Bradley - OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5025331","version":"1","preferredName":"Aspirate Plasma Cell Percentage Value","preferredDefinition":"The numeric value in percentage related to the plasma cells in a bone marrow aspirate.","longName":"ASP_BM_PLASM_PTG_VAL_2DEC","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"209C613F-6C83-0425-E050-BB89AD43744C","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-09-25","modifiedBy":"BRADLAUR","dateModified":"2015-09-29","changeNote":"New CDE curated by L. Bradley - OHSU Knight","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5027815","version":"1","preferredName":"Plasma Cell Myeloma Molecule Receptor Number Value","preferredDefinition":"Number of myeloma molecules sensitive to a receptor used to assess minimal residual disease by sequencing.","longName":"MYE_MLCL_RECP_NUM_VAL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"213F2EDB-EBD5-97AD-E050-BB89AD436E21","latestVersionIndicator":"Yes","beginDate":"2015-10-03","endDate":null,"createdBy":"BRADLAUR","dateCreated":"2015-10-03","modifiedBy":"BRADLAUR","dateModified":"2015-10-06","changeNote":"New CDE curated by L. Bradley (OHSU Knight)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5038394","version":"1","preferredName":"Gene Mutation Abnormality Variant Descriptive Text","preferredDefinition":"A text term that describes the gene mutation variant.","longName":"Gene_Variant","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22FCDB3E-D9E0-B5BE-E050-BB89AD4376F8","latestVersionIndicator":"Yes","beginDate":"2015-10-26","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-10-26","modifiedBy":"NIKITAP","dateModified":"2022-02-23","changeNote":"Created new non-specific CDE to capture gene variant information.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045114","version":"1","preferredName":"Leukemia Cutis Patient Observation Indicator","preferredDefinition":"An indicator of Yes, No, Not Applicable or Unknown to ask if there is evidence observed of cutaneous involvement by an acute or chronic leukemia. [manually curated]","longName":"LEUK_CUTIS_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24755597-49AE-19D5-E050-BB89AD430E78","latestVersionIndicator":"Yes","beginDate":"2015-11-13","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-11-13","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed CDE to indicate observed evidence of leukemia cutis in a patient.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045115","version":"1","preferredName":"Heart Echocardiogram Test  Indicator","preferredDefinition":"An indicator of yes, no, unknown or not applicable to indicate whether an echocardiogram (ECHO) test was performed [manually curated].","longName":"ECHO_TEST_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"247631BD-D7D8-6EF0-E050-BB89AD43513F","latestVersionIndicator":"Yes","beginDate":"2015-11-13","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-11-13","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20_ghd; Needed to create new CDE to add 'Not applicable' option.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5045116","version":"1","preferredName":"Chest X-ray Assessment Indicator","preferredDefinition":"A yes, no, unknown or not applicable indicator of whether a chest x-ray was assessed. [manually curated]","longName":"CHEST_XR_ASSESS_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"247631BD-D816-6EF0-E050-BB89AD43513F","latestVersionIndicator":"Yes","beginDate":"2015-11-13","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-11-13","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20_ghd; Needed to curate new CDE to include NA value.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5067131","version":"1","preferredName":"Cytogenetic Analysis Assessment Performed Indicator","preferredDefinition":"A yes, no, unknown or not applicable indicator that determines whether a cytogenetic analysis was performed (information related to an examination of the body through analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities).  [manually curated]","longName":"CYTO_ASS_PERF_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"25F2D197-0321-F96B-E050-BB89AD435A67","latestVersionIndicator":"Yes","beginDate":"2015-12-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-12-02","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20_ghd; Needed to curate new CDE to allow Yes/No/Unk or NA option with this concept (rather than a Done/ Not done) for consistency with similar questions on the study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5076372","version":"1","preferredName":"Laboratory Specimen Not Collected Indicator","preferredDefinition":"An indicator code of whether a laboratory sample was not collected (1 indicates not collected, 0 indicates it was collected). [manually curated]","longName":"LAB_NOT_COLLECTED","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26527575-3C67-0B4A-E050-BB89AD433FB6","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2015-12-07","modifiedBy":"MARTINEZW","dateModified":"2017-06-29","changeNote":"Needed a new CDE to work with RAVE checkbox functionality that resolves to 0 or 1 only.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5133434","version":"1","preferredName":"17p / p53 Gene Cytogenetic Abnormality Present Indicator","preferredDefinition":"An indicator of whether a cytogenetic abnormality in chromosome 17p / p53 gene was present [manually curated].","longName":"CYTO_17p_p53_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C92E274-4C28-65F2-E050-BB89AD437855","latestVersionIndicator":"Yes","beginDate":"2016-02-25","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-25","modifiedBy":"FOURNIERLA","dateModified":"2016-02-25","changeNote":"Needed new CDE for CRF question \"Is cytogenetic 17p/p53 present?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5133438","version":"1","preferredName":"17p / p53 Gene Abnormality Fluorescence in Situ Hybridization Present  Indicator","preferredDefinition":"An indicator of whether an abnormality in chromosome 17p / p53 gene was present in Fluorescence in Situ Hybridization (FISH) result [manually curated].","longName":"FISH_17p_p53_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C92E274-4C6D-65F2-E050-BB89AD437855","latestVersionIndicator":"Yes","beginDate":"2016-02-25","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-25","modifiedBy":"FOURNIERLA","dateModified":"2016-02-25","changeNote":"Needed new DE for CRF question \"FISH result: Is 17p/p53 present?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143777","version":"1","preferredName":"BTK Gene Sequencing Performed Indicator","preferredDefinition":"An indicator of whether sequencing was performed for Bruton's Tyrosine Kinase (BTK), a gene is involved in both signaling and B-cell development [manually curated].","longName":"BTK_SEQ_PERF_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CED0D20-191D-E283-E050-BB89AD430637","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"FOURNIERLA","dateModified":"2016-02-29","changeNote":"Needed new DE for \"Was BTK sequencing performed?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143834","version":"1","preferredName":"Ion Semiconductor (Ion Torrent) Gene Sequencing Performed Indicator","preferredDefinition":"An indicator of whether sequencing was performed using an ion semiconductor sequencing (Ion Torrent) platform [manually curated].","longName":"ION_SEQ_PERF_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEEB3D3-57A6-9D55-E050-BB89AD434FBC","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE for \"Was sequencing using the ion torrent platforms performed?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143876","version":"1","preferredName":"Study Participant Data Ready For Interim Analysis Statistics Indicator","preferredDefinition":"An indicator of whether study participant data is ready for interim statistical analysis [manually curated].","longName":"INT_ANALYSIS_READY","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEF407A-C7DC-4AF3-E050-BB89AD436F89","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Need new CDE: \"Is study participant ready for interim analysis?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143895","version":"1","preferredName":"Equivocal Progression Assessment Requiring Follow Up Indicator","preferredDefinition":"An indicator of whether there exists equivocal progression of most or all non-target disease that requires follow-up [manually curated].","longName":"EQUIVPROG_FU_REQ","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEF407A-C82C-4AF3-E050-BB89AD436F89","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE: \"Are there equivocal progression of most or all non-target disease that requires follow-up?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143911","version":"1","preferredName":"New Lesion Equivocal Assessment Requiring Follow-up Indicator","preferredDefinition":"An indicator of whether there are equivocal new lesion(s) that require follow-up [manually curated].","longName":"EQUIVNEW_LES_FU_REQ","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CEF407A-C85C-4AF3-E050-BB89AD436F89","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE: \"Are there new equivocal lesion(s) that require follow-up?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143957","version":"1","preferredName":"Disease Progression Free Last Verification Less Enrollment Date Calculation Value","preferredDefinition":"The number of days from the date the patient was enrolled on the study to the date the patient was last verified to be free of progression [manually curated].","longName":"PFS_DAYS_ENROLL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF0D295-EC12-83C1-E050-BB89AD431A7F","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE for Progression Free Survival (PFS): Total number of days since study enrollment","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143961","version":"1","preferredName":"Gene Variant Detected Indicator","preferredDefinition":"An indicator of whether a protocol specified genetic variant was detected [manually curated].","longName":"VARIANT_DETECTED","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF17B46-8E32-913B-E050-BB89AD434764","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"NIKITAP","dateModified":"2022-02-23","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE for \"Variant detected?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5143991","version":"1","preferredName":"Palpable Lymph Node Fine-Needle Aspiration Biopsy Indicator","preferredDefinition":"information relating to the biopsy or removal of palpable lymphatic tissue or fluid with a fine needle for examination under a microscope._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"LYMPH_NODE_FNA_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CF20F00-C8F1-BD67-E050-BB89AD432467","latestVersionIndicator":"Yes","beginDate":"2016-02-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-02-29","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20_ghd; needed new CDE that wasn't specific to armpit/axillary","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5145514","version":"1","preferredName":"Gene Expression Profiling Performed Indicator","preferredDefinition":"An indicator of whether gene expression profiling was performed [manually curated].","longName":"GENEPROFILE_PERF_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D1805D6-D2EF-4840-E050-BB89AD436430","latestVersionIndicator":"Yes","beginDate":"2016-03-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-03-02","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE for CRF question 'Was gene expression profiling using Lymph5Cx test performed?'","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5148675","version":"1","preferredName":"Patient Achieve Overall Objective Disease Response Indicator","preferredDefinition":"An indicator of whether a patient achieved an overall objective response (OOR) [manually curated].","longName":"OOR_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D1D6D01-C178-6E40-E050-BB89AD437BFC","latestVersionIndicator":"Yes","beginDate":"2016-03-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-03-02","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE \"Did patient achieve OOR?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5148694","version":"1","preferredName":"Induction Related Death Indicator","preferredDefinition":"An indicator of whether cause of subject death was related to induction (neoadjuvant therapy) [manually curated].","longName":"INDUCTION_DEATH_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D1E7AAF-FF33-A8F7-E050-BB89AD436727","latestVersionIndicator":"Yes","beginDate":"2016-03-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-03-02","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE for 'Is this an induction related death?'","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5148714","version":"1","preferredName":"Hematologic or Infectious Disorder Complication Indicator","preferredDefinition":"An indicator of whether a given adverse event was associated with either a hematologic or infection complication [manually curated].","longName":"HEME_INFECT_COMP","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D1E7AAF-FF77-A8F7-E050-BB89AD436727","latestVersionIndicator":"Yes","beginDate":"2016-03-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-03-02","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new AE CDE: Was this a hematologic or infection complication?","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5148734","version":"1","preferredName":"Patient Delay Marrow Recovery Fulfill Criteria Indicator","preferredDefinition":"An indicator of whether patient has met criteria for delayed marrow recovery [manually curated].","longName":"DELAY_MARROW_REC","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D1E7AAF-FFC3-A8F7-E050-BB89AD436727","latestVersionIndicator":"Yes","beginDate":"2016-03-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-03-03","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new CDE for: Did patient meet criteria for delayed marrow recovery?","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5203554","version":"1","preferredName":"BTK Gene Mutation Detection Indicator","preferredDefinition":"An indicator of whether a mutation was detected in the BTK gene (Bruton's Tyrosine Kinase), a gene involved in both signaling and B-cell development [manually curated].","longName":"BTK_MUT_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EE17C72-7D94-1C75-E050-BB89AD431128","latestVersionIndicator":"Yes","beginDate":"2016-03-25","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-03-25","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20_ghd; Needed new DE for \"Was BTK mutation detected?\"_Released during quarterly metrics clean up_12.03.20_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237070","version":"1","preferredName":"Person Clinical Trial Repeat Screening Reason Text","preferredDefinition":"A free text field that describes the reason that a subject will undergo repeat of screening procedures for a clinical trial [manually curated].","longName":"RE_SCREEN_REASON","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A61F74-06CB-A7EF-E050-BB89AD433EE4","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-04-29","modifiedBy":"FOURNIERLA","dateModified":"2016-04-29","changeNote":"Needed new CDE for study 7195 - reason for re-screen.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5237071","version":"1","preferredName":"Person Clinical Trial Repeat Screening Indicator","preferredDefinition":"A yes, no indicator that describes whether subject will undergo repeat of screening procedures for a clinical trial [manually curated].","longName":"RE_SCREEN_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31A79F3E-53F3-B04E-E050-BB89AD437C6E","latestVersionIndicator":"Yes","beginDate":"2016-04-29","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-04-29","modifiedBy":"SPRINGERL","dateModified":"2020-06-05","changeNote":"Needed new CDE for new question \"Is this a re-screen?\"","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5242115","version":"1","preferredName":"Subject Discontinue Trial Screening Reason Other Specify Text","preferredDefinition":"Text describing reason why a subject will not continue with processes to consider them as potential subjects for enrollment in a research conducted on human subjects [manually curated].","longName":"DISCONT_SCRN_REAS_OTH","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31E17E92-778F-2840-E050-BB89AD432A6A","latestVersionIndicator":"Yes","beginDate":"2016-05-02","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-05-02","modifiedBy":"FOURNIERLA","dateModified":"2016-05-02","changeNote":"Needed Other specify question for reason not continuing w/ screening.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5270701","version":"1","preferredName":"Clinical Study Protocol Agent Without Modification or Adjustment Administered Yes No Unknown Indicator","preferredDefinition":"An indicator to specify whether a study agent intervention was administered as specified per protocol without modification, delay or adjustment [manually curated].","longName":"AGENT_ADM_WOUT_MOD","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33236E39-1214-489A-E050-BB89AD433CA4","latestVersionIndicator":"Yes","beginDate":"2016-05-18","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-05-18","modifiedBy":"FOURNIERLA","dateModified":"2016-05-18","changeNote":"Needed  CDE to indicate study intervention administered without modification. [lf-5/18/2016]","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5272094","version":"1","preferredName":"Concomitant Agent Or Concomitant Intervention or Procedure Administration Report Date","preferredDefinition":"The date a concomitant agent or procedure (an agent or procedure that is not part of the protocol regimen, and are generally used for treatment of preexisting conditions or symptoms, and for adverse events) was reported. [Manually-curated]","longName":"CONMED_RPT_DT","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"334AE373-C974-08DC-E050-BB89AD4310FF","latestVersionIndicator":"Yes","beginDate":"2016-05-20","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-05-20","modifiedBy":"HARTLEYG","dateModified":"2020-12-03","changeNote":"Released during quarterly metrics clean up_12.03.20; Released during quarterly metrics clean up_12.03.20_ghd; Released during quarterly metrics clean up_12.03.20_ghd; Needed new  Conmed report date CDE. (5/20/2016 lara fournier)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5335711","version":"1","preferredName":"Patient Physical Examination Response Assessment Code","preferredDefinition":"An indicator code of whether a physical exam was performed (1 indicates not performed, 0 indicates it was peformed)","longName":"EXAM_NOT_DONE_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36EB5B68-E8B2-7A7C-E050-BB89AD43359E","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-07-05","modifiedBy":"FOURNIERLA","dateModified":"2016-07-05","changeNote":"Needed a new CDE for a Not done chkbox option used in Medidata Rave physical exam form. [Lara Fournier]","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5340851","version":"1","preferredName":"Response Confirmed Indicator","preferredDefinition":"The yes/no/unknown indicator to ask if response was confirmed by a second assessment, additional tests, investigator, review panel or other protocol specified criteria.","longName":"RESP_CONF_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"372A0B99-9A0C-34C4-E050-BB89AD435E9E","latestVersionIndicator":"Yes","beginDate":"2016-07-08","endDate":"2016-09-01","createdBy":"FOURNIERLA","dateCreated":"2016-07-08","modifiedBy":"FOURNIERLA","dateModified":"2016-09-01","changeNote":"s. Needed general (non-specific) response confirmed CDE. lcf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5369251","version":"1","preferredName":"Transfusion Last Year Information Collected Indicator","preferredDefinition":"The yes/no/unknown/not applicable response regarding whether information pertaining to any transfusions has been collected for the past year.","longName":"TRANS_LAST_YR_COLL_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"390C11B6-E34A-6A50-E050-BB89AD435B2A","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-08-01","modifiedBy":"FOURNIERLA","dateModified":"2016-08-01","changeNote":"Study team needed N/A value option to old orig. CDE 45302534 so needed to curate new CDE for study 10262 - lcf.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5369291","version":"1","preferredName":"Other Mutation Abnormality Allele Burden Assessment Specify","preferredDefinition":"The alphanumeric text response regarding the measurement of the percentage ratio between mutant and wild type genes, other than those previously specified, in hematopoietic cells.","longName":"OT_MU_AL_BUR_SPEC","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"390CC5B1-4665-27B1-E050-BB89AD4348F5","latestVersionIndicator":"Yes","beginDate":"2016-08-01","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-08-01","modifiedBy":"FOURNIERLA","dateModified":"2016-08-01","changeNote":"Study team needed text value option to old orig. CDE 4566694 so needed to curate new.  lcf.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455311","version":"1","preferredName":"Disease Post Treatment Condition Status","preferredDefinition":"The current status (controlled, uncontrolled or unknown) of disease following treatment, intervention or therapy.","longName":"DX_COND_STATUS","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C03581C-A4BA-593C-E050-BB89AD4304B1","latestVersionIndicator":"Yes","beginDate":"2016-09-08","endDate":null,"createdBy":"FOURNIERLA","dateCreated":"2016-09-08","modifiedBy":"BRADLAUR","dateModified":"2016-09-09","changeNote":"needed new CDE for reflecting whether disease was controlled following treatment. 9/8/2016 (study 10262) - lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5653757","version":"1","preferredName":"Chemotherapy Induction Nausea and Vomiting Questionnaire Difficulty Falling Asleep Last Score Difficulty Falling Asleep 11 Point Scale","preferredDefinition":"A person's stated observation of how much difficulty they had falling asleep last, using an 11 point visual analog scale.","longName":"CINV_FALL_ASLEEP_SCL","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47AA54E1-2CE9-52B4-E053-F662850AAE74","latestVersionIndicator":"Yes","beginDate":"2017-02-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-03","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.03.17_ghd, reviewed&released 2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5653762","version":"1","preferredName":"Meal Usual Day Eat Number","preferredDefinition":"A person's response stating the number of meals they typically eat in a day.","longName":"MEAL_TYP_DAY_EAT_NUM","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47AB17DA-0FCF-36AB-E053-F662850A1854","latestVersionIndicator":"Yes","beginDate":"2017-02-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-03","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.03.17_ghd, reviewed & released 2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655068","version":"1","preferredName":"Meal Past 24 Hours Eat Number","preferredDefinition":"The response that indicates the number of meals an individual has eaten within the past 24 hours.","longName":"MEAL_P24HR_EAT_NUM","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E10928-348D-6405-E053-F662850A7379","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.06.17_ghd, reviewed and released 2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655069","version":"1","preferredName":"Chemotherapy Induction Nausea and Vomiting Questionnaire Percentage Food Eat Score Percentage Food Eaten 11 Point Scale","preferredDefinition":"A person's stated observation the percentage of the total food they ate of the meals consumed, using an 11 point visual analog scale.","longName":"CINV_PCT_FOOD_EAT_SC","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E1FF13-5C90-622F-E053-F662850A7E7E","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.06.17_ghd, reviewed and released 2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655070","version":"1","preferredName":"Vomiting Past 24 Hours Occurrence Number","preferredDefinition":"The response indicating the number of occurrences of vomiting that occurred in the past 24 hours.","longName":"VOMIT_P24HR_OCC_NUM","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E1E4D9-CC00-5BD2-E053-F662850AF0AE","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.06.17_ghd, reviewed and released 2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655071","version":"1","preferredName":"Nausea Past 24 Hours Occurrence Yes No Indicator","preferredDefinition":"The response indicating whether a person experienced any nausea within the past 24 hours.","longName":"NAUSEA_P24HR_OCC_IND","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E1E4D9-CC20-5BD2-E053-F662850AF0AE","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.06.17_ghd, reviewed/released _2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655072","version":"1","preferredName":"Chemotherapy Induction Nausea and Vomiting Questionnaire Past 24 Hours Nausea Score Nausea 11 Point Scale","preferredDefinition":"A person's stated observation of how much nausea they had in the last 24 hours, using an 11 point visual analog scale.","longName":"CINV_P24HR_NAUSEA_SC","contextName":"OHSU Knight","contextVersion":"1","dataElementConceptPublicId":"2192191","dataElementConceptVersion":"1","valueDomainPublicId":"3775994","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E2E2FD-45FB-0190-E053-F662850AC711","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"FOURNIERLA","dateModified":"2017-02-08","changeNote":"OHSU_02.06.17_ghd, reviewed and released 2.8.2017_lf","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}]}